1. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study
- Author
-
Emanuel, Della-Torre, Corrado, Campochiaro, Giulio, Cavalli, Giacomo, De Luca, Angela, Napolitano, Salvatore, La Marca, Nicola, Boffini, Valentina, Da Prat, Gaetano, Di Terlizzi, Marco, Lanzillotta, Patrizia, Rovere Querini, Annalisa, Ruggeri, Giovanni, Landoni, Moreno, Tresoldi, Fabio, Ciceri, ALberto, Zangrillo, Francesco, De Cobelli, Lorenzo, Dagna, Alberto, Zangrillo, Della-Torre, E., Campochiaro, C., Cavalli, G., De Luca, G., Napolitano, A., La Marca, S., Boffini, N., Da Prat, V., Di Terlizzi, G., Lanzillotta, M., Rovere Querini, P., Ruggeri, A., Landoni, G., Tresoldi, M., Ciceri, F., Zangrillo, A., De Cobelli, F., and Dagna, L.
- Subjects
Male ,Time Factors ,Epidemiology ,Bacteremia ,Azithromycin ,Severity of Illness Index ,Lopinavir ,Cohort Studies ,therapeutics ,Immunology and Allergy ,Enzyme Inhibitors ,Lung ,anti-inflammatory agents, non-steroidal ,biology ,Coinfection ,Interleukin ,Middle Aged ,Anti-Bacterial Agents ,Drug Combinations ,C-Reactive Protein ,Treatment Outcome ,Italy ,Administration, Intravenous ,Female ,Coronavirus Infections ,Hydroxychloroquine ,Cohort study ,medicine.medical_specialty ,Pneumonia, Viral ,Immunology ,Antibodies, Monoclonal, Humanized ,Antiviral Agents ,General Biochemistry, Genetics and Molecular Biology ,Betacoronavirus ,Rheumatology ,Internal medicine ,Severity of illness ,medicine ,Humans ,Interleukin 6 ,Pandemics ,Proportional Hazards Models ,Noninvasive Ventilation ,Ritonavir ,Interleukin-6 ,SARS-CoV-2 ,Proportional hazards model ,business.industry ,Oxygen Inhalation Therapy ,COVID-19 ,medicine.disease ,Receptors, Interleukin-6 ,COVID-19 Drug Treatment ,Blockade ,Sarilumab ,Pneumonia ,inflammation ,biology.protein ,Tomography, X-Ray Computed ,business - Abstract
ObjectivesTo assess the safety and efficacy of interleukin (IL)−6 blockade with sarilumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation.MethodsWe conducted an open-label study of sarilumab in severe COVID-19 pneumonia (PaO2/FiO2 ResultsTwenty-eight patients were treated with sarilumab and 28 contemporary patients receiving standard of care alone were used as controls. At day 28 of follow-up, 61% of patients treated with sarilumab experienced clinical improvement and 7% died. These findings were not significantly different from the comparison group (clinical improvement 64%, mortality 18%; p=NS). Baseline PaO2/FiO2 ratio >100 mm Hg and lung consolidation ConclusionsAt day 28, overall clinical improvement and mortality in patients with severe COVID-19 were not significantly different between sarilumab and standard of care. Sarilumab was associated with faster recovery in a subset of patients showing minor lung consolidation at baseline.
- Published
- 2020
- Full Text
- View/download PDF